What are the optimal antihypertensive medications for secondary prevention in patients who have had an ischemic or hemorrhagic stroke?

Best Antihypertensives for Secondary Stroke Prevention

For patients with prior stroke or TIA, initiate blood pressure-lowering therapy with an ACE inhibitor plus a thiazide diuretic (or alternatively an angiotensin receptor blocker plus thiazide diuretic) targeting BP <130/80 mmHg, as this combination provides the most robust evidence for reducing recurrent stroke, major vascular events, and mortality. 1, 2

Long-Term Blood Pressure Targets

• Target BP <130/80 mmHg for most stroke survivors, as endorsed by the 2021 AHA/ASA guidelines and supported by contemporary evidence showing optimal secondary prevention at this threshold 1, 3, 4

• The 2024 ESC guidelines recommend a slightly narrower systolic range of 120-130 mmHg, though the practical difference is minimal 1, 3

• Avoid excessive BP lowering below 120/70 mmHg, as this may increase risk without additional benefit, though the exact threshold for harm remains incompletely defined 5

Preferred Antihypertensive Agents

First-Line Combination Therapy

ACE inhibitors plus thiazide diuretics represent the gold standard based on the landmark PROGRESS trial, which demonstrated:

• 28% reduction in recurrent stroke (both ischemic and hemorrhagic)
• 26% reduction in major coronary events
• 26% reduction in major vascular events
• The combination (perindopril plus indapamide) achieved mean BP reduction of 12.3/5.0 mmHg and was effective regardless of baseline hypertension status 2

Angiotensin receptor blockers (ARBs) plus thiazide diuretics are equally acceptable alternatives, with some evidence suggesting potential superiority:

• The MOSES trial showed eprosartan prevented vascular events more effectively than the calcium channel blocker nitrendipine despite similar BP reductions 6
• ARBs may offer cerebroprotective effects beyond BP lowering through differential activation of angiotensin II type 2 receptors 6

Alternative First-Line Options

Calcium channel blockers are appropriate alternatives, particularly when ACE inhibitors or ARBs are contraindicated 7

Additional thiazide diuretics can be added to any regimen for enhanced BP control 1, 7

Agents to Avoid or Use Selectively

Beta-blockers should be reserved for specific indications (e.g., concurrent coronary artery disease, heart failure, atrial fibrillation requiring rate control) rather than routine secondary stroke prevention, as they lack the robust stroke-specific evidence of other drug classes 7

Timing of Initiation

Acute Phase (First 72 Hours)

For ischemic stroke patients:

• Do NOT routinely lower BP in the first 72 hours unless BP ≥220/120 mmHg 1, 3
• If BP is extremely elevated (≥220/120 mmHg), consider modest reduction of 10-15% over several hours 1, 3
• Exception: Patients receiving IV thrombolysis or mechanical thrombectomy require BP <185/110 mmHg before treatment and <180/105 mmHg for 24 hours post-treatment 1, 8

For hemorrhagic stroke patients:

• Initiate rapid BP lowering within 6 hours targeting systolic BP 140-160 mmHg to prevent hematoma expansion 1, 3
• Avoid excessive acute drops >70 mmHg from baseline, particularly when initial systolic BP ≥220 mmHg, due to risk of acute kidney injury and neurological deterioration 1, 3

Subacute Phase (After 72 Hours)

Initiate or reintroduce antihypertensive therapy before hospital discharge for all patients with BP ≥140/90 mmHg 1

This early initiation improves long-term adherence and outcomes 1

Evidence Strength and Nuances

The combination of ACE inhibitor plus thiazide diuretic has the strongest evidence base from the PROGRESS trial (2003), which remains the definitive study for secondary stroke prevention despite its age 2. More recent meta-analyses confirm that intensive BP control (targeting <130/80 mmHg) provides superior protection against recurrent stroke (RR 0.87), cardiovascular deaths (RR 0.75), and all-cause mortality (RR 0.85) compared to standard BP control 4.

The 2025 comparative guideline review confirms convergence across major international guidelines (AHA, ESC, ESH, JSH) on these core principles, with only minor regional variations in specific BP targets 3.

Common Pitfalls to Avoid

• Do not aggressively lower BP in acute ischemic stroke (first 72 hours) unless treating for thrombolysis/thrombectomy or BP ≥220/120 mmHg, as cerebral autoregulation may be impaired and perfusion depends on systemic pressure 1, 8

• Do not use ACE inhibitor or ARB monotherapy when combination therapy with a diuretic is feasible—the PROGRESS trial showed monotherapy (perindopril alone) achieved only 4.9/2.8 mmHg reduction with minimal stroke prevention benefit, while combination therapy was highly effective 2

• Do not continue patients on beta-blockers alone for stroke prevention without a compelling cardiac indication 7

• Avoid excessive BP variability and overshoot during acute management, particularly in hemorrhagic stroke 1